Últimas noticias sobre Amgen (NASDAQ:AMGN) Bolsa

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Inc

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

News

Health Care

Media

General

AMGN

EXEL

GILD

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

<a href="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic" title="https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic">https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic</a>

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

TERN

VANI

VKTX

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 45% bullish and 36%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $372,685, and 5 are calls, for a total amount of $171,796.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $282.5 for Amgen, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $220.0 to $282.5 over the preceding 30 days.
<h3>Amgen Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734030989_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.05</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$270.00</td>
<td>$152.0K</td>
<td>1.3K</td>
<td align="right">822</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.3</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$270.00</td>
<td>$54.9K</td>
<td>1.3K</td>
<td align="right">148</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$3.1</td>
<td>$2.86</td>
<td>$2.98</td>
<td>$267.50</td>
<td>$50.4K</td>
<td>625</td>
<td align="right">170</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$3.75</td>
<td>$2.69</td>
<td>$2.94</td>
<td>$267.50</td>
<td>$45.0K</td>
<td>625</td>
<td align="right">180</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.25</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$270.00</td>
<td>$43.8K</td>
<td>1.3K</td>
<td align="right">427</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,698,248, the AMGN's price is down by -0.17%, now at $272.95. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 54 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Amgen

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$28.7K</td>
<td>19.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CADL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.00</td>
<td>$44.6K</td>
<td>1.2K</td>
<td>995</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.7K</td>
<td>27.4K</td>
<td>566</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$75.00</td>
<td>$70.6K</td>
<td>95</td>
<td>286</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$35.2K</td>
<td>5.8K</td>
<td>273</td>
</tr>
<tr>
<td>AMED</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>6.3K</td>
<td>250</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$37.6K</td>
<td>1.0K</td>
<td>148</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$55.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>130</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$123.5K</td>
<td>217</td>
<td>48</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$105.00</td>
<td>$34.0K</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $287.0 per contract. There were 19843 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• Regarding CADL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), we observe a call option sweep with bearish sentiment. It expires in 9 day(s) on December 20, 2024. Parties traded 372 contract(s) at a $6.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $44.6K, with a price of $120.0 per contract. There were 1230 open contracts at this strike prior to today, and today 995 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 401 day(s) on January 16, 2026. This event was a transfer of 101 contract(s) at a $25.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $285.0 per contract. There were 27415 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option sweep that happens to be bearish, expiring in 282 day(s) on September 19, 2025. This event was a transfer of 286 contract(s) at a $75.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $70.6K, with a price of $247.0 per contract. There were 95 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with neutral sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $235.0 per contract. There were 5818 open contracts at this strike prior to today, and today 273 contract(s) were bought and sold. 
• Regarding AMED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), we observe a put option trade with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $147.5K, with a price of $590.0 per contract. There were 6378 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 37 day(s) on January 17, 2025. This event was a transfer of 8 contract(s) at a $580.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $4710.0 per contract. There were 1038 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 2 day(s) on December 13, 2024. This event was a transfer of 100 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1033 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 47 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $123.5K, with a price of $2630.0 per contract. There were 217 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 44 day(s) on January 24, 2025. Parties traded 32 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $1065.0 per contract. There were 32 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMED

CADL

RXRX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

The dividend will be paid on March 7, 2025, to all stockholders of record as of the close of business on February 14, 2025.

Dividends

Amgen Boosts Q1 Dividend By 6% From $2.25 To $2.38 Per Share

During the last three months, 13 analysts shared their evaluations of Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Amgen and provided 12-month price targets. The average target is $340.38, accompanied by a high estimate of $405.00 and a low estimate of $215.00. This upward trend is evident, with the current average reflecting a 0.18% increase from the previous average price target of $339.78.
<img src="https://www.benzinga.com/files/images/story/2024/1733835712_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Amgen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$256.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$335.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$326.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Yaron Weber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$381.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$380.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$333.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$405.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$362.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amgen. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amgen's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amgen analyst ratings.</a>
<h2>Get to Know Amgen Better</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Financial Insights: Amgen</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Amgen's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.18% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 33.28%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Amgen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 42.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.11%, the company showcases effective utilization of assets.
Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 8.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Amgen: Insights From 13 Analyst Reviews

B of A Securities analyst Tim Anderson reinstates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Underperform and announces $256 price target.

Price Target

Initiation

B of A Securities Reinstates Underperform on Amgen, Announces $256 Price Target

Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) today announced&nbsp;new data demonstrating that adding BLINCYTO&#xAE; (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4319894-1&amp;h=1897591024&amp;u=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2411680&amp;a=published">published</a>&nbsp;in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8, at 2 p.m. PT at the 66th American Society of Hematology (ASH) Annual Meeting &amp; Exposition in San Diego.
Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone.

Amgen Announced Blincyto Added To Chemotherapy Significantly Improves Survival In Newly Diagnosed Pediatric Patients With B-cell Precursor Acute Lymphoblastic Leukemia At ASH; Said Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$270.00</td>
<td>$126.0K</td>
<td>711</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$160.00</td>
<td>$162.3K</td>
<td>2.0K</td>
<td>939</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$310.00</td>
<td>$54.2K</td>
<td>71</td>
<td>742</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$830.00</td>
<td>$28.3K</td>
<td>2.0K</td>
<td>520</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$600.00</td>
<td>$96.7K</td>
<td>17</td>
<td>474</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$240.00</td>
<td>$279.3K</td>
<td>1.0K</td>
<td>306</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$89.1K</td>
<td>8.4K</td>
<td>289</td>
</tr>
<tr>
<td>MEDP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$25.8K</td>
<td>224</td>
<td>178</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$29.4K</td>
<td>4.1K</td>
<td>145</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$390.00</td>
<td>$28.2K</td>
<td>348</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 13, 2024. This event was a transfer of 618 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $126.0K, with a price of $205.0 per contract. There were 711 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on March 21, 2025. This event was a transfer of 800 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $162.3K, with a price of $203.0 per contract. There were 2021 open contracts at this strike prior to today, and today 939 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option sweep with bullish sentiment. It expires in 197 day(s) on June 20, 2025. Parties traded 21 contract(s) at a $310.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $2582.0 per contract. There were 71 open contracts at this strike prior to today, and today 742 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 13 contract(s) at a $830.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $2176.0 per contract. There were 2007 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on December 27, 2024. Parties traded 117 contract(s) at a $600.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $96.7K, with a price of $830.0 per contract. There were 17 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 6, 2024. Parties traded 266 contract(s) at a $240.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $279.3K, with a price of $1050.0 per contract. There were 1000 open contracts at this strike prior to today, and today 306 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be neutral, expiring in 43 day(s) on January 17, 2025. This event was a transfer of 99 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $89.1K, with a price of $900.0 per contract. There were 8479 open contracts at this strike prior to today, and today 289 contract(s) were bought and sold. 
• Regarding MEDP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), we observe a put option sweep with bullish sentiment. It expires in 15 day(s) on December 20, 2024. Parties traded 30 contract(s) at a $340.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $860.0 per contract. There were 224 open contracts at this strike prior to today, and today 178 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be neutral, expiring in 771 day(s) on January 15, 2027. This event was a transfer of 70 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $420.0 per contract. There were 4153 open contracts at this strike prior to today, and today 145 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 47 contract(s) at a $390.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $600.0 per contract. There were 348 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

MEDP

&nbsp;Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M Commitment
THOUSAND OAKS, Calif., Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.

Amgen Announces A $1B Expansion To Establish A Second Drug Substance Manufacturing Facility In North Carolina; Bringing The Company's Total Planned Investment In Holly Springs To More Than $1.5B, Building On Its Previously Announced $550M Commitment

<a href="https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf" title="https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf">https://www.medscape.com/viewarticle/ada-advises-against-using-compounded-glp-1-ra-medications-2024a1000m0u?form=fpf</a>

'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) new drug candidate, MariTide, reported promising results, helping patients <a href="https://www.benzinga.com/topic/weight-loss-drugs">shed around 20%</a> of their body weight.
But when up against the current titans — Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) — "promising" may not cut it.
<h2 class="wp-block-heading">Weight Loss: A Tough Market For Newcomers</h2>
Eli Lilly and Novo Nordisk's drugs, Zepbound and Wegovy, aren't just treatments—they're juggernauts. Amgen's MariTide enters the fray with a unique antibody-peptide mechanism, which could offer less frequent dosing and potentially fewer rebounds in weight. Yet, with side effects like nausea and vomiting in 70% of patients, it's a tough sell in a market where first impressions matter.
Read Also: <a href="https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plateau">Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau</a>
As Nicholas Anderson of Thornburg Investment Management <a href="https://www.livemint.com/companies/eli-lilly-and-novo-nordisk-s-obesity-moat-just-got-stronger-11733036578455.html">points</a> out, "A 20% weight loss would have been best-in-class a few years ago. But Novo Nordisk and Eli Lilly have drugs in the pipeline that could meet or exceed 25% weight loss." 
Worse for Amgen, MariTide is still in phase 2, while Lilly and Novo's next-generation drugs are nearly ready for market.
<h2 class="wp-block-heading">The Pfizer-Merck Parallel</h2>
Pharma history suggests dominance isn't guaranteed—Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) statin Mevacor paved the way in the 1980s but was eventually outpaced by Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Lipitor. 
However, with obesity drugs, the first movers seem poised to stay on top. Despite Amgen's potential 10% market share, it's hard to see MariTide displacing the leaders in what some are calling "the greatest pharmaceutical bonanza of all time."
<h2 class="wp-block-heading">A Big Market, Even For The Underdogs</h2>
Amgen doesn't need to dethrone Lilly and Novo to win. Even a small slice of the projected $100 billion market is lucrative. MariTide's once-monthly injection offers manufacturing efficiencies and cardiovascular perks, as noted by BMO Capital Markets analyst Evan Seigerman.
For now, Amgen may only nibble at the obesity market pie, but the stakes are massive. Whether it's a scrappy upstart or a next-gen titan, one thing is certain—the weight-loss wars are just getting started.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42192091/biden-proposes-medicare-medicaid-access-for-popular-weight-loss-drugs">Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs</a></li>
</ul>
Image: Shutterstock

Long Ideas

Trading Ideas

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.00</td>
<td>$127.4K</td>
<td>2.2K</td>
<td>5.0K</td>
</tr>
<tr>
<td>NMRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$86.5K</td>
<td>4.5K</td>
<td>827</td>
</tr>
<tr>
<td>SRRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$27.7K</td>
<td>3.2K</td>
<td>805</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/06/24</td>
<td>$105.00</td>
<td>$28.5K</td>
<td>901</td>
<td>558</td>
</tr>
<tr>
<td>RVMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$55.00</td>
<td>$55.4K</td>
<td>704</td>
<td>461</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$285.00</td>
<td>$31.0K</td>
<td>1.1K</td>
<td>439</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$91.00</td>
<td>$49.3K</td>
<td>28</td>
<td>413</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$200.00</td>
<td>$108.0K</td>
<td>280</td>
<td>212</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.00</td>
<td>$109.2K</td>
<td>365</td>
<td>105</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.50</td>
<td>$25.3K</td>
<td>11.2K</td>
<td>66</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For ADMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on December 20, 2024. This event was a transfer of 1499 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $127.4K, with a price of $85.0 per contract. There were 2293 open contracts at this strike prior to today, and today 5072 contract(s) were bought and sold. 
• For NMRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>), we notice a put option sweep that happens to be bullish, expiring in 46 day(s) on January 17, 2025. This event was a transfer of 309 contract(s) at a $7.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $86.5K, with a price of $280.0 per contract. There were 4550 open contracts at this strike prior to today, and today 827 contract(s) were bought and sold. 
• Regarding SRRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), we observe a call option trade with bearish sentiment. It expires in 46 day(s) on January 17, 2025. Parties traded 99 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $27.7K, with a price of $280.0 per contract. There were 3264 open contracts at this strike prior to today, and today 805 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option sweep with bullish sentiment. It expires in 4 day(s) on December 6, 2024. Parties traded 250 contract(s) at a $105.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $114.0 per contract. There were 901 open contracts at this strike prior to today, and today 558 contract(s) were bought and sold. 
• For RVMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), we notice a call option sweep that happens to be bearish, expiring in 18 day(s) on December 20, 2024. This event was a transfer of 426 contract(s) at a $55.00 strike. This particular call needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $135.0 per contract. There were 704 open contracts at this strike prior to today, and today 461 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 18 day(s) on December 20, 2024. Parties traded 100 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $310.0 per contract. There were 1197 open contracts at this strike prior to today, and today 439 contract(s) were bought and sold. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a call option sweep that happens to be bullish, expiring in 11 day(s) on December 13, 2024. This event was a transfer of 411 contract(s) at a $91.00 strike. This particular call needed to be split into 48 different trades to become filled. The total cost received by the writing party (or parties) was $49.3K, with a price of $120.0 per contract. There were 28 open contracts at this strike prior to today, and today 413 contract(s) were bought and sold. 
• Regarding BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we observe a call option trade with bearish sentiment. It expires in 136 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $200.00 strike. The total cost received by the writing party (or parties) was $108.0K, with a price of $540.0 per contract. There were 280 open contracts at this strike prior to today, and today 212 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a put option trade with bearish sentiment. It expires in 200 day(s) on June 20, 2025. Parties traded 50 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $109.2K, with a price of $2185.0 per contract. There were 365 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 410 day(s) on January 16, 2026. Parties traded 54 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $25.3K, with a price of $470.0 per contract. There were 11285 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA

BIIB

NMRA

RVMD

SAVA

SRRK

10 Health Care Stocks With Whale Alerts In Today's Session

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Outperform and lowers the price target from $360 to $330.

RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330

<h3>Gainers</h3>
<ul>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares moved upwards by 224.5% to $9.28 during Tuesday's pre-market session. The company's market cap stands at $904.4 million. </li>
<li>Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) stock rose 23.76% to $2.5. The company's market cap stands at $226.3 million. </li>
<li>Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares increased by 21.07% to $22.75. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q4 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock rose 19.47% to $26.66. The market value of their outstanding shares is at $396.0 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock increased by 18.12% to $22.35. The market value of their outstanding shares is at $536.3 million. </li>
<li>Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) stock increased by 18.04% to $17.01. The market value of their outstanding shares is at $981.5 million. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) shares declined by 43.8% to $21.75 during Tuesday's pre-market session. The company's market cap stands at $2.8 billion. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock declined by 34.35% to $2.6. The company's market cap stands at $254.6 million. </li>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) shares fell 20.77% to $55.01. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares decreased by 17.85% to $2.9. The market value of their outstanding shares is at $2.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) stock declined by 10.14% to $1.95. The company's market cap stands at $19.8 million. </li>
<li>Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 9.94% to $264.78. The market value of their outstanding shares is at $142.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALEC

ARWR

BTSGU

COCP

CRBU

EMBC

NGNE

PSTX

SCNI

TCMD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's <a href="https://www.benzinga.com/topic/interest-rates">November meeting minutes</a>. 
Reports are expected to provide fresh critical insights into the central bank's outlook for interest rates. Fed futures currently assign a 59% probability of a 25-basis-point rate cut in December. The remaining odds suggest the Fed may hold rates steady in the 4.5%-4.75% range, as per CME FedWatch.
Fed futures are currently assigning a 59% chance to a 25-basis-point Fed rate cut in December, while remaining odds point to the option of holding rates steady at 4.5%-4.75%, as per CME FedWatch. 
<h3 class="wp-block-heading">25% Tariffs On All Imports</h3>
In a relatively quiet trading session, both Mexican and Canadian assets saw a surge in volatility after President-elect Donald Trump pledged to <a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">raise tariffs to 25% on all imports from Mexico and Canada</a>, citing efforts to combat drug trafficking and illegal immigration.
The Mexican peso dropped 2.5%, falling to 22.80 per U.S. dollar, a level of weakness not seen since August 2022. The iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) also declined sharply, tumbling 2.9%.
President Claudia Sheinbaum responded with a retaliatory warning, suggesting Mexico could impose its own tariffs, escalating the risk of economic damage for both nations.
The Canadian dollar fared slightly better, sliding 0.7% but still reaching its lowest level in more than four years.
U.S. Treasury yields ticked higher, reversing some of the sharp declines seen on Monday following President-elect Trump's announcement of Scott Bessent as his pick for Treasury Secretary. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.5%, cooling off after Monday's 2.6% rally.
Gold traded flat, remaining near $2,010 per ounce. Oil prices fell 0.8% to $68.30 per barrel, as markets monitored developments around the ceasefire deal between Israel and Hezbollah as the Israeli Security Cabinet meets for the official approval.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose slightly by 0.7%, after logging its worst single-day performance in more than four months on Monday. 
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% (1-day)</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,013.26</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,891.08</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,656.98</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,426.91</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:52 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged 0.4% higher to $596.83, eyeing the seventh straight session of gains.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $447.10.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.5% up to $508.98.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.4% to $241.28.</li>
<li>The&nbsp;Utilities Sector Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1%. The&nbsp;Materials Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 0.9%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Shares of automakers fell after President-elect Donald Trump threatened tariffs on goods <a href="https://www.benzinga.com/news/global/24/11/42196251/general-motors-stellantis-lead-automaker-stock-declines-as-trump-proposes-aggressive-tariffs-on-mexico-canada">imported from Canada and Mexico.</a> Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) were down 2.3%, 8.4% and 5.3%, respectively. For GM this may potentially mark the worst day since August 2021. </li>
<li>Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) rose 5.4% while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) tumbled over 8%, after the latter saw weight-loss drug results coming in below analyst expectations. </li>
<li>Zoom Video Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) fell over 7% in reaction to quarterly earnings. </li>
<li>Other stocks reacting to quarterly results included Semtech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>), up 18%, Analog Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>), down 3%, Agilent Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), down 1.8%, Woodward Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>), up 6%, Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), down 7%, Dicks Sporting Goods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), down 0.2%, VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>), up 1%. </li>
</ul>
Check Out:
<ul>
<li><a href="https://www.benzinga.com/general/psychology/24/11/42196027/amazon-dominates-holiday-shopping-as-black-friday-spending-soars-goldman-sachs">Amazon Dominates Holiday Shopping As Black Friday Spending Soars: Goldman Sachs</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Mid Cap

Broad U.S. Equity ETFs

Emerging Markets

Emerging Market ETFs

Commodities

Politics

Global

Econ #s

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

SMTC

STLA

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariff Fears: What's Driving Markets Tuesday?

The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has faced backlash for the steep prices of Wegovy and Ozempic, two popular <a href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets">drugs in this category.</a>
While Novo Nordisk&#8217;s CEO&nbsp;Lars Fruergaard Jørgensen&nbsp;has defended the high U.S. prices of the company&#8217;s blockbuster drugs,&nbsp;Ozempic&nbsp;and&nbsp;Wegovy, stating that these medications are reducing the economic burden of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-" rel="noreferrer noopener">obesity-related health issues</a>.
Recent advancements in anti-obesity medications have demonstrated the potential to prevent Type 2 diabetes and reduce cardiovascular-related mortality by up to 20%.
However, the steep cost of these medications—often as high as $1,000 per month without insurance—places them beyond reach for many Americans.
The proposed rule <a target="_blank" href="https://www.whitehouse.gov/briefing-room/statements-releases/2024/11/26/fact-sheet-biden-harris-administration-takes-latest-step-to-lower-prescription-drug-costs-by-proposing-expanded-coverage-of-anti-obesity-medications-for-americans-with-medicare-and-medicaid/" rel="noreferrer noopener">seeks</a> to make these treatments more accessible, benefiting an estimated 3.4 million Medicare recipients and 4 million Medicaid enrollees. For some, the expanded coverage could cut out-of-pocket expenses by up to 95%.
The Department of Health and Human Services (HHS) highlighted the disparity between U.S. and international drug prices, with Americans paying significantly more for anti-obesity medications.
The proposed expansion aligns with broader efforts to lower drug costs through negotiations and increased competition, aiming to ensure life-saving treatments are affordable and accessible.
According to some analysts, Novo Nordisk&#8217;s blockbuster diabetes drug Ozempic might be included in the next round of Medicare <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">drug price negotiations</a>.
Most recently, Novo Nordisk said it will officially launch its weight-loss drug Wegovy in China. A four-injection pack costs around $194 (CNY 1,400) compared to around $1,349 per patient&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42041147/novo-nordisk-to-offer-wegovy-in-china-at-fraction-of-usa-cost" rel="noreferrer noopener">per month in the U.S</a>.
In the third quarter, Wegovy sales reached 17.30 billion Danish kroner, up 81%, and Ozempic sales increased 26% at constant currency to 29.80 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41775675/ozempicwegovy-maker-maintains-q3-sales-growth-on-booming-demand" rel="noreferrer noopener">billion Danish kroner</a>.
&#8220;The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments,&#8221; Jørgensen said.
As per a report in August, several older Americans are having little success getting prescriptions for Wegovy, covered by Medicare, despite the federal healthcare program&#8217;s decision to pay for&nbsp;patients with obesity&nbsp;at <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy" rel="noreferrer noopener">risk of heart disease</a>.
Price Action: NVO stock is up 1.7% at $106.41 at last check Tuesday.
The stocks of several pharmaceutical companies involved in developing or marketing weight-loss medications showed mixed performance as of Tuesday&#8217;s publication.
<ol>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) was up 3.9% to $785.49.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) was down 11.4% to $260.84.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) was down 1.3% to $25.81.</li>
<li>Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) was up 5.2% to $54.74.</li>
</ol>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/42187787/intel-to-receive-nearly-8-billion-in-federal-funding-under-chips-act-for-us-expansion" target="_blank" rel="noreferrer noopener">Intel To Receive Nearly $8 Billion In Federal Funding Under CHIPS Act for US Expansion</a></li>
</ul>
Photo by lev radin on Shutterstock

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

On Tuesday, Amgen&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42185604/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52" rel="noreferrer noopener">in obese patients</a>.
The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks.
Amgen&#8217;s stock dropped as the results seemed to fall short of Wall Street&#8217;s high expectations. CNBC noted that analysts had hoped MariTide would achieve at least 20% weight loss in the Phase 2 trial, with some <a target="_blank" href="https://www.cnbc.com/2024/11/26/amgen-says-weight-loss-drug-maritide-caused-up-to-20percent-weight-loss-after-a-year.html" rel="noreferrer noopener">aiming</a> for as much as 25%.
The study also showed that a subset of patients who typically lose less weight on GLP-1 therapies achieved up to ~17% average weight loss without a weight loss plateau, lowering their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52.
MariTide also demonstrated improvements in cardiometabolic parameters, including blood pressure, triglycerides, and high-sensitivity C-reactive protein (hs-CRP) across doses. There were no significant increases in free fatty acids.
There was no association between the administration of MariTide and bone mineral density changes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-impact-on-bone-density" rel="noreferrer noopener">Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide&#8217;s Impact on Bone Density</a>
The most common side effects were gastrointestinal, including vomiting, nausea, and constipation. Amgen said the discontinuation rate in the dose escalation arms due to any AE was ~11% and less than 8% for GI-related events. No additional safety signals were identified.
In a separate ongoing Phase 1 pharmacokinetic study, additional dosing regimens have been evaluated in a planned preliminary analysis.
The ongoing Part 2 of the Phase 2 study is investigating MariTide beyond 52 weeks to evaluate further weight loss with continued treatment, weight maintenance through less frequent or lower dosing and durability of weight loss after discontinuation of MariTide.
MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent single-injection administration.
Amgen is also advancing its obesity pipeline, including oral and injectable approaches composed of incretin and non-incretin mechanisms.
Price Action: AMGN stock is down 11.6% at $259.88 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42188320/best-buy-says-q3-sales-little-softer-than-expected-on-lower-demand-for-appliances-and-gaming-trims-annual-forecast" target="_blank" rel="noreferrer noopener">Best Buy Says Q3 Sales &#8216;Little Softer Than Expected&#8217; On Lower Demand For Appliances And Gaming, Trims Annual Forecast</a></li>
</ul>
Photo via Shutterstock.

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

WIIM

Amgen shares are trading lower following the results of its Phase 2 study with MariTide in obesity.

<ul>
<li>MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight</li>
<li>MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study</li>
<li>In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage Points at 52 Weeks</li>
<li>MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters</li>
<li>Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions</li>
</ul>

Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the field. Given the robust prospect, investors looking for fundamentally sound biotech stocks might consider adding Regeneron Pharmaceuticals (REGN), Amgen (AMGN), and Gilead Sciences (GILD) to their portfolio. Read on… Thanks to groundbreaking advancements in precision medicine and immunotherapy, the biotech industry is undergoing a transformative phase, particularly in cancer treatment. The companies are reshaping the way cancer is diagnosed and treated with innovations.
Below, I have highlighted three fundamentally strong biotech stocks: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), which are well-positioned for long-term growth with their research breakthroughs.
Immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors, has been a <a href="https://www.yalemedicine.org/news/how-immunotherapy-can-treat-cancer-and-autoimmune-diseases">game-changer for cancer treatment</a>. These approaches enable the immune system to recognize and attack cancer cells more effectively. Companies pioneering such therapies are seeing robust growth, driven by the high efficacy and increasing adoption of their treatments.
With the global cancer burden increasing, the demand for innovative treatments is also surging. In the third quarter of 2024, the US Food and Drug Administration (FDA) <a href="https://www.aacr.org/blog/2024/10/03/fda-approvals-in-oncology-july-september-2024/">approved 16 oncology drugs</a>, including six new agents and 25 expanded indications for existing drugs.
The global biotechnology market is anticipated to <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reach $3.88 trillion by 2030</a>, exhibiting a CAGR of 13.9%. The market is driven by strong government support, improvement in approval processes, and standardization of clinical studies. Companies with strong pipelines and innovative therapies stand to gain as these treatments revolutionize the healthcare landscape.
With that in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, starting with the third choice.
Stock #3: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.  The company's products include EYLEA injection, Dupixent Injection, Libtayo Injection, Praluent Injection, Kevzara Injection, and others.
On December 9, REGN announced new and positive data for odronextamab monotherapy in patients with previously untreated follicular lymphoma with twelve abstracts spanning several B-cell non-Hodgkin lymphoma (B-NHL) subtypes. It demonstrates the effectiveness of the paradigm-changing potential of the odronextamab development program.
As per Elizabeth Brém, Associate Clinical Professor, Division of Hematology/Oncology at UC Irvine, "The OLYMPIA-1 Phase 3 trial is designed to explore a novel, chemotherapy-free, fixed duration treatment that is being studied in the outpatient setting in patients with previously untreated follicular lymphoma."
On November 6, REGN received approval from the European Commission for Dupixent&#xAE; (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1 to 11 years. This approval expands EoE in adults and adolescents, creating a milestone in treating pediatric patients. 
REGN, for the third quarter (ended September 30, 2024), reported total revenues of $3.72 billion, indicating a 10.6% growth from the prior-year quarter. Its income from operations increased 6.2% year-over-year to $1.18 billion. The company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $1.46 billion and $12.46 per share, up 10% and 7.5% year-over-year, respectively.
The consensus revenue estimate of $3.63 billion for the fiscal first quarter (ending March 2025) represents a 15.4% increase year-over-year. The consensus EPS estimate of $10.95 for the same quarter indicates a 14.6% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
The stock has gained marginally intraday to close the last trading session at $788.
REGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
REGN has a B grade for Value and Quality. It is ranked #27 out of 332 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/REGN/">Click here</a> to see the additional ratings for REGN (Growth, Momentum, Stability, and Sentiment).
Stock #2: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics globally. The company's product portfolio includes Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA.
On December 7, AMGN announced new data that demonstrates adding BLINCYTO&#xAE; (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones.
The same week, AMGN announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This expansion will help AMGN to meet the growing demand for therapies and enhance the company's global biomanufacturing network.
For the third quarter of 2024, which ended on September 30, AMGN's total revenues increased 23.2% year-over-year, amounting to $8.50 billion. The company reported non-GAAP income from operations of $4.04 billion, indicating an 18.8% increase from the prior-year quarter.
In addition, AMGN's non-GAAP net income came in at $3.02 billion, up 13.4% year-over-year, while its non-GAAP net income per share grew 12.5% from the year-ago value to $5.58. Its adjusted free cash flow rose 31.9% from the year-ago value to $3.31 billion.
As per the updated financial guidance for the full year 2024, AMGN now forecasts revenue to be in the range of $33 billion to $33.80 billion and its non-GAAP EPS between $19.20 and $20.
Street expects AMGN's revenue for the fiscal fourth quarter (ending December 2024) to increase 8% year-over-year to $8.85 billion. Its EPS for the same period is expected to register a 6.8% growth from the prior year, settling at $5.03. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters, which is promising.
AMGN's stock has surged 3.2% over the past year to close the last trading session at $277.63.
AMGN's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth and Quality. Within the same industry, it is ranked #18 out of 332 stocks. <a href="https://stocknews.com/stock/AMGN/">Click here</a> to see AMGN's ratings for Value, Momentum, Stability, and Sentiment.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company dedicated to advancing treatments for life-threatening diseases such as human immunodeficiency virus (HIV), viral hepatitis, COVID-19, and cancer.  Its portfolio of marketed products includes Biktarvy, Genvoya, Odefsey, Truvada, Harvoni, Vemlidy, and Veklury, among others.
On December 9, GILD announced positive results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas including follicular lymphoma or marginal zone lymphoma. Dr. Sattva S. Neelapu, lead investigator at the University of Texas MD Anderson Cancer Center, believes that such impressive results may have a curative effect on difficult-to-treat blood cancers.
In the same month, GILD and Tubulis entered an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. Under this agreement, GILD will gain access to Tubulis' proprietary Tubutecan and Alco5 platforms, and Tubulis will receive a payment of $20 million. This agreement will allow GILD to explore a range of solutions to help increase the therapeutic value of the ADC modality.
In the fiscal second quarter, which ended on June 30, 2024, GILD's total revenues increased 5.4% year-over-year to $6.95 billion. The company reported operating income of $2.64 billion, indicating 58.8% growth from the prior-year quarter. GILD's non-GAAP net income attributable came in at $2.52 billion, up 49.2% year-over-year, while its non-GAAP EPS grew 50% from the year-ago value to $2.01.
According to the full-year guidance, GILD forecasts product sales to range from $27.10 billion to $27.50 billion. The company also expects non-GAAP EPS to be between $3.60 and $3.90, an increase from the previous guidance of $6.85 to $7.25.
Analysts expect GILD's revenue and EPS for the current year (ending December 2024) to be $28.30 billion and $4.42, respectively. For the fiscal year 2025, its revenue and EPS are expected to grow marginally, and 69.8% from the prior year to $28.31 billion and $7.50, respectively.
Over the past six months, the stock has gained 40%, closing the last trading session at $90.59.
GILD's strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and Sentiment and a B for Growth and Quality. The stock is ranked first in the Biotech industry. <a href="https://stocknews.com/stock/GILD/">Click here</a> to access the additional GILD ratings (Momentum and Stability).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $276.77 per share on Tuesday afternoon, down $0.86 (-0.31%). Year-to-date, AMGN has declined -1.00%, versus a 28.22% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/amgn-gild-regn-3-biotech-stocks-revolutionizing-cancer-treatment/>3 Biotech Stocks Revolutionizing Cancer Treatment</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Revolutionizing Cancer Treatment

Amgen raises quarterly dividend by 5.8% to  $2.38/share

BofA restarts coverage of 11 large-cap biopharmas

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The company's shar...

Oppenheimer Remains a Buy on Amgen (AMGN)

The biotech sector's AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on... The biotech sector is poised for a significant boom in 2025, driven by innovative adaptive trial designs that cut time and costs while enhancing drug efficacy predictions. This favorable landscape presents an opportunity for investors to explore fundamentally strong biotech stocks with promising pipelines: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>).
The biotech sector is revolutionizing healthcare by targeting new and rare diseases with cutting-edge vaccines and therapies, driven by the rising demand for personalized medicine. Regulatory agencies like the FDA and EMA are streamlining processes to match technological advancements, propelling the global biotechnology market toward a projected $3.88 trillion by 2030, with an impressive <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Notably, AI and machine learning are transforming drug discovery by optimizing molecule screening and improving clinical outcome analysis. Beyond oncology and neurology, AI is driving advancements across diverse therapeutic areas. Deloitte estimates that biopharma companies investing in AI over the next five years could see up to an <a href="https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html">11% increase</a> in value relative to revenue across various functional areas.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 20.6% returns over the past year. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, VRTX's 39.89% is considerably higher than the 2.49% industry average. Likewise, its 28.83% trailing-12-month levered FCF margin is significantly higher than the 2.32% industry average. Furthermore, its 0.48x trailing-12-month asset turnover ratio is 17.3% higher than the 0.41x industry average.
VRTX's net revenues for the third quarter, which ended on September 30, 2024, increased 11.6% year-over-year to $2.77 billion. Its non-GAAP net income stood at $1.05 billion, or $4.01 per share, up 7.5% and 7.4%, respectively, compared to the prior-year quarter. Furthermore, its non-GAAP operating income rose 11.4% year-over-year to $1.31 billion.
Street expects VRTX's revenue for the quarter ending December 31, 2024, to increase 10.5% year-over-year to $2.78 billion. Its EPS for fiscal 2025 is expected to grow considerably year-over-year to $18.79. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, VRTX's stock has gained 30.4% to close the last trading session at $464.50.
VRTX's positive outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Value, Stability, and Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #21 out of 335 stocks in the Biotech industry. Beyond what we stated above, we also have given VRTX grades for Growth, Momentum, and Quality. Get all the VRTX ratings <a href="https://stocknews.com/stock/VRTX/">here</a>.
Stock #2: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its product portfolio includes Enbrel, Neulasta, Prolia, and Xgeva.
On September 24, 2024, AMGN announced that TEPEZZA (Teprotumumab) has been approved in Japan for treating active Thyroid Eye Disease (TED), making it the first and only approved treatment in the country. The approval is based on positive Phase 3 trial results, with additional trials ongoing for chronic TED patients.
AMGN's trailing-12-month gross profit margin of 60.59% is 4.1% higher than the industry average of 58.20%. Likewise, its trailing-12-month EBIT margin and levered FCF margin of 20.51% and 14.06% are 723.3% and 505.5% higher than the industry averages of 2.49% and 2.32%, respectively.
During the fiscal third quarter, which ended on September 30, 2024, AMGN's total revenues and non-GAAP operating income increased by 23.2% and 18.8% year-over-year, reaching $8.50 billion and $4.04 billion, respectively. Moreover, its non-GAAP net income grew 13.4% compared to the previous year, reaching $3.02 billion. Also, its non-GAAP net income per share grew 12.5% from the year-ago value to $5.58.
Analysts expect AMGN's revenue for the quarter ending December 31, 2024, to increase 8.1% year-over-year to $8.86 billion. Its EPS for the same quarter is expected to grow 7.1% year-over-year to $5.04. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained marginally closing the last trading session at $274.78.
AMGN's POWR Ratings reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system.
AMGN has a B grade for Growth and Quality. Within the same industry, it is ranked #17. <a href="https://stocknews.com/stock/AMGN/">Click here</a> for the additional POWR Ratings of AMGN (Value, Momentum, Stability, and Sentiment).
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
On December 3, 2024, GILD and Tubulis announced an exclusive option and license agreement to develop an antibody-drug conjugate (ADC) for a solid tumor target. The collaboration leverages Tubulis' advanced ADC platforms and GILD's oncology expertise to address challenges like durability and off-target toxicity.
On September 10, 2024, GILD and Genesis Therapeutics announced a collaboration to use Genesis' GEMS AI platform to discover and optimize small molecule therapies for selected targets. GILD gains exclusive rights to develop and commercialize the resulting compounds.
In terms of the trailing-12-month EBITDA margin, GILD's 49.29% is 763.7% higher than the 5.71% industry average. Likewise, its 77.80% trailing-12-month gross profit margin is 33.7% higher than the 58.20% industry average. Its 0.48x trailing-12-month asset turnover ratio is 17.5% higher than the 0.41x industry average.
In the fiscal third quarter, which ended on September 30, 2024, GILD's total revenues increased 7% year-over-year to $7.55 billion. The company's non-GAAP operating income was $3.26 billion, up 1.1% from the previous year's quarter. Additionally, its non-GAAP net income attributable to GILD stood at $2.53 billion, or $2.02 per share.
For the quarter ending December 31, 2024, GILD's revenue is expected to increase marginally year-over-year to $7.15 billion. Its EPS for fiscal 2025 is expected to grow 71.4% year-over-year to $7.56. GILD surpassed the EPS estimates in three of the trailing four quarters. Over the past six months, the stock has gained 41.4% to close the last trading session at $91.77.
It's no surprise that GILD has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It is ranked first in the Biotech industry. It has an A grade for Value and a B for Growth, Sentiment, and Quality. <a href="https://stocknews.com/stock/GILD/">Click here</a> to see GILD's Momentum and Stability ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $273.03 per share on Thursday afternoon, down $0.38 (-0.14%). Year-to-date, AMGN has declined -2.34%, versus a 28.52% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/amgn-vrtx-gild-3-biotech-stocks-with-promising-pipelines/>3 Biotech Stocks With Promising Pipelines</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks With Promising Pipelines

The Dow Jones Industrial Average is falling on Friday as it prepares to close out the week red as several stocks drag it down.

A Dissapointing Week for Dow Jones Industrial Average Sees the Index Close in the Red

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value

DJD: The Dogs Of The Dow ETF Not Ideal Heading Into 2025

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

AAPL

ABBV

ADBE

ALLE

AMZN

APLO

AVGO

AZNCF

BCPC

BKNG

BSVN

CABO

CARR

CBSH

CCBG

CINF

CMCSA

COST

CSCO

CSGS

CTVA

DJIA

ENSG

EPRT

ERIE

EVRG

EXPO

FRME

GOLF

GOOG

GOOGL

IDOWF

INTC

INVH

ISRG

JJSF

JKHY

KFRC

KLIC

LAND

MBWM

MDLZ

MRNA

MSFT

NDAQ

NFLX

NRIM

NVDA

ODFL

OFLX

OLED

ORCL

OTEX

PRGO

QCOM

RBCAA

REGN

SAMG

SBUX

SDOW

SEIC

SWBI

TCBK

TMUS

TSLA

TTWO

UBCP

UBER

UDOW

VCTR

VICI

VRTX

WDFC

Press Releases

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

Legal

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Amgen

Noticias

Últimas noticias sobre Amgen (NASDAQ:AMGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL